Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05359133 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
A Phase 2 study, sponsored by Wex Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
NCT05359133: Clinical Trial Phase 2 study, sponsored by Wex Pharmaceuticals.
NCT05359133 is a Phase 2 study that was terminated before completion, run by Wex Pharmaceuticals. The registered enrollment target is 35 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05359133, a Phase 2 study, was terminated before completion, sponsored by Wex Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
Study Summary
To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.
Interventions
- DRUG Placebo
- DRUG Tetrodotoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2024-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05359133
The ClinicalTrials.gov registry entry for NCT05359133 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wex Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05359133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05359133 about?
NCT05359133 is a clinical study titled "A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain". To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomizati...
What is the current status of trial NCT05359133?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-04-19. Estimated completion is 2024-10-14.
What interventions are being tested in trial NCT05359133?
The interventions under investigation include: Placebo (DRUG), Tetrodotoxin (DRUG).
Who is sponsoring clinical trial NCT05359133?
This trial is sponsored by Wex Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.